logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
E

Esther Oomen-de Hoop

erasmus university medical center
H指数:31
被引数:3,260

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study

司美格鲁肽降低阿来替尼的生物利用度：一项基于交叉药代动力学药物相互作用研究的警告说明

Cancer Communications
IF24.9
2025-05-010
OAAI
Niels Heersche; Daan A. C. Lanser; Esther Oomen-de Hoop; Attila Içli; Peter de Bruijn; Marthe S. Paats; Elisabeth F. C. van Rossum; Stijn L. W. Koolen; Ron H. N. van Schaik; Anne-Marie C. Dingemans; G. D. Marijn Veerman; Ron H. J. Mathijssen
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial

曲氟尿苷替匹嘧啶用于既往治疗过的雌激素受体阳性、HER2阴性转移性乳腺癌患者（BOOG 2019-01 TIBET试验）：一项单臂、多中心、II期临床试验

ECLINICALMEDICINE
IF10
2025-02-010
PRE
Guchelaar, Niels A. D.; Mathijssen, Ron H. J.; de Boer, Maaike; van Bekkum, Marlies L.; Heijns, Joan B.; Vriens, Birgit E. P. J.; van Rosmalen, Mandy M.; Kessels, Lonneke W.; Hamming, Lisanne; Beelen, Karin J.; Nieboer, Peter; van den Berg, Susan M.; Oomen-de Hoop, Esther; Bijlsma, Rhode M.; Bos, Monique E. M. M.
The added value of a new high-performance ring-gantry CBCT imaging system for prostate cancer patients

新型高性能环形龙门式CBCT成像系统对前列腺癌患者的附加价值

RADIOTHERAPY AND ONCOLOGY
IF5.3
2024-11-014
PRE
Kunnen, Britt; Schoot, Agustinus J. A. J. van de; Fremeijer, Kimm P.; Nicolai-Koornneef, Elise M.; Offereins-van Harten, Kirsten; Sluijter, Judith H.; Sijtsema, Nienke D.; Oomen-de Hoop, Esther; el Yaakoubi, Abdelmounaim; Froklage, Femke E.; de Vries, Kim C.; Dirkx, Maarten L. P.; Penninkhof, Joan J.; Petit, Steven F.
Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib

共有的胚系变异对阿来替尼毒性特征和药代动力学的影响

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Heersche, N.; Lanser, D. A. C.; Muntinghe, B.; Ali, M. I. Mohmaed; Ulas, E. B.; Trooster, T. M. A.; de Jonge, E.; Oomen-de Hoop, E.; Paats, M. S.; Bahce, I.; Croes, S.; Hendriks, L. E.; Van der Wekken, A. J.; Dingemans, A-M. C.; Huitema, A. D. R.; Van Schaik, R.; Mathijssen, R. H.; Veerman, M. G. D.
Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study

曲氟尿苷替匹嘧啶在经治ER阳性、HER2阴性转移性乳腺癌患者中的II期研究：荷兰BOOG（2019-01 TIBET）研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Guchelaar, N. A. D.; Mathijssen, R. H.; De Boer, M.; van Bekkum, M. L.; Heijns, J. B.; Vriens, B. E. P. J.; Kessels, L. W.; Hamming, L. C.; Beelen, K. J.; Nieboer, P.; van Rosmalen, M. M.; van den Berg, S. M.; Oomen-de Hoop, E.; Bijlsma, R. M.; Bos, M. M. E. M.
Dose-individualisation of fluoropyrimidines in DPYD wild-type patients: Final results from the Alpe2U study

氟嘧啶类药物的剂量个体化在DPYD野生型患者中的研究：Alpe2U研究的最终结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Heersche, N.; Knikman, J. E.; De With, M.; Lopez-Yurda, M.; Baars, A.; Creemers, G-J.; Droogendijk, H.; Fiets, E.; Deenen, M.; Van Schaik, R.; van den Bosch, B.; Oomen-de Hoop, E.; Rosing, H.; Swen, J.; Gelderblom, H.; Schellens, J. H. M.; Beijnen, J. H.; Mathijssen, R. H.; Guchelaar, H-J.; Cats, A.
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol
BMC CANCER
IF3.4
2024-05-232
OAAI
Janssen, J. C.; van Dijk, B.; de Joode, K.; Aarts, M. J. B.; van den Berkmortel, F. W. P. J.; Blank, C. U.; Boers-Sonderen, M. J.; van den Eertwegh, A. J. M.; de Groot, J. W. B.; Jalving, M.; de Jonge, M. J. A.; Joosse, A.; Kapiteijn, E.; Kamphuis-Huismans, A. M.; Naipal, K. A. T.; Piersma, D.; Rikhof, B.; Westgeest, H. M.; Vreugdenhil, G.; Oomen-de Hoop, E.; Mulder, E. E. A. P.; van der Veldt, Astrid A. M.
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
EBIOMEDICINE
IF10.8
2024-04-017
OAAI
Ernst, Sophie M.; Hofman, Maaike M.; van der Horst, Tessa E.; Paats, Marthe S.; Aerts, Joachim G. J. V.; Heijboer, Frank W. J.; Dumoulin, Daphne W.; Cornelissen, Robin; von der Thusen, Jan H.; de Bruijn, Peter; Hoop, Esther Oomen-de; Mathijssen, Ron H. J.; Koolen, Stijn L. W.; Dingemans, Anne -Marie C.

研究方向

暂未获取到该数据
R
Ron H.J. Mathijssen
H 指数:76论文数:888被引数:2.0万
S
Stijn L.W. Koolen
H 指数:30论文数:257被引数:3,532
A
Astrid A.M. van der Veldt
H 指数:44论文数:361被引数:6,997
P
Peter de Bruijn
H 指数:38论文数:265被引数:7,222
S
Sander Bins
H 指数:22论文数:98被引数:1,781
A
Agnes Jager
H 指数:61论文数:472被引数:1.6万
J
Joachim G.J.V. Aerts
H 指数:70论文数:662被引数:3.0万
J
Joost J. Nuyttens
H 指数:44论文数:295被引数:8,683
A
Arjen Joosse
H 指数:17论文数:80被引数:1,397
A
Anne‐Marie C. Dingemans
H 指数:71论文数:674被引数:2.0万